SelectQuote (SLQT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Sep, 2026Executive summary
Annual Meeting scheduled for November 10, 2026, to be held virtually, with voting available online, by phone, or mail.
Record date for voting eligibility is September 18, 2026; only stockholders of record on this date may vote.
Five proposals will be presented, including director elections, auditor ratification, executive compensation, a reverse stock split, and potential adjournment.
Board recommends voting FOR all proposals.
Voting matters and shareholder proposals
Proposal 1: Election of three Class I directors to serve until 2029.
Proposal 2: Ratification of Deloitte & Touche LLP as independent auditor for fiscal year ending June 30, 2027.
Proposal 3: Non-binding advisory vote to approve executive compensation (say-on-pay).
Proposal 4: Reverse stock split (1-for-10 to 1-for-20) and corresponding reduction in authorized shares.
Proposal 5: Adjournment proposal to solicit additional proxies if needed for the reverse stock split.
Board recommends FOR all proposals; quorum requires majority of outstanding shares.
Board of directors and corporate governance
Board consists of eight directors, majority independent, with staggered three-year terms.
Board leadership is separated between CEO and independent Chairman.
Committees include Audit, Compensation and Talent Development, Nominating and Corporate Governance, and Healthcare Oversight.
Director nominations consider diversity, experience, and stockholder recommendations.
Stockholder engagement program and communication channels are in place.
Latest events from SelectQuote
- Key votes include director elections, auditor ratification, and a proposed reverse stock split.SLQT
Proxy filing - Annual Meeting to vote on director elections, auditor ratification, executive pay, and a reverse stock split.SLQT
Proxy filing - Revenue and cash flow grew in 2026; 2027 targets higher margins and efficiency gains.SLQT
Q4 2026 - Diversified insurance and healthcare platform achieves strong growth and operational efficiency.SLQT
Investor presentation - Q3 FY2026 revenue up 6% to $430.9M, net income $40.2M, with robust segment growth and outlook.SLQT
Q3 2026 - Revenue up 12% to $537.1M, net income $69.3M, and guidance cut by $40M amid external headwinds.SLQT
Q2 2026 - FY2024 results surpassed expectations, with robust growth in revenue and profitability.SLQT
Q4 2024 - Revenue up 26% with strong pharmacy growth; $100M securitization boosts capital flexibility.SLQT
Q1 2025 - Q2 revenue up 19% to $481.1M, net income $53.2M, $350M equity investment secured.SLQT
Q2 2025